Developments Aeglea BioTherapeutics gets FDA breakthrough designation for pegzilarginase Aeglea BioTherapeutics’ (NASDAQ:AGLE) pegzilarginase received FDA breakthrough therapy designation for the treatment of arginase 1 deficiency (ARG1-D). ARG1-D is a rare genetic childhood disease that causes severe... July 25, 2019